Financial HealthWith a cash position of $883 million and a maturing clinical pipeline across multiple therapeutic areas, Immunocore is well positioned for continued growth.
Pipeline ProgressImmunocore's T cell receptor (TCR) bispecific immunotherapies are progressing well with multiple, potentially value-creating near-term catalysts in the next 12 months.
Therapeutic AdvancementsThe positive results from Immatics' PRAME-targeted T cell therapy reinforce the potential of Immunocore’s brenetafusp program.